KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) EBIT Margin: 2009-2025

Historic EBIT Margin for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -14.38%.

  • Neogenomics' EBIT Margin fell 175.00% to -14.38% in Q3 2025 from the same period last year, while for Sep 2025 it was -17.04%, marking a year-over-year decrease of 272.00%. This contributed to the annual value of -13.94% for FY2024, which is 427.00% up from last year.
  • Neogenomics' EBIT Margin amounted to -14.38% in Q3 2025, which was up 45.23% from -26.27% recorded in Q2 2025.
  • In the past 5 years, Neogenomics' EBIT Margin ranged from a high of -10.70% in Q4 2024 and a low of -44.40% during Q1 2022.
  • For the 3-year period, Neogenomics' EBIT Margin averaged around -17.02%, with its median value being -15.92% (2023).
  • As far as peak fluctuations go, Neogenomics' EBIT Margin crashed by 3,746bps in 2021, and later surged by 1,884bps in 2023.
  • Quarterly analysis of 5 years shows Neogenomics' EBIT Margin stood at -33.06% in 2021, then soared by 1,404bps to -19.02% in 2022, then surged by 708bps to -11.94% in 2023, then soared by 124bps to -10.70% in 2024, then tumbled by 175bps to -14.38% in 2025.
  • Its last three reported values are -14.38% in Q3 2025, -26.27% for Q2 2025, and -16.56% during Q1 2025.